Rare Disease Report

Huntingtons Disease

Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.
Upon unearthing rheumatoid arthritis’ epigenome, researchers at University of California San Diego School of Medicine and the Icahn School of Medicine at Mount Sinai have also discovered an overlap between the causes of rheumatoid arthritis and Huntington’s disease.
PTC Therapeutics, Inc. and the CDHI Foundation Inc. are partnering for a research collaboration that will hopefully advance the former’s Huntington’s disease program.
Results from a recent study found that the mutated huntingtin gene in patients with HD generates a class of small molecules that are highly toxic to cancer cells, but not healthy cells.
A study published in the journal eLife suggests that blocking an enzyme could reduce levels of the mutant huntingtin (mHTT) protein.
This new infographic from Rare Disease Report provides 5 little-known facts about the Huntington's disease that might not necessarily be covered in news articles. 
Teva Pharmaceuticals, the HDSA, and the ALS Association are partnering for the Teva CNS Target Identification Challenge, a crowdsourcing effort to seek novel targets with therapeutic potential.
It was recently revealed that a newly-discovered biochemical pathway could assist scientists develop new ways to protect cells against the oxidative stress that is commonly associated with Huntington’s disease.
Ionis Pharmaceuticals reported positive top-line data from a completed Phase 1/2 study of RG6042 (Ionis HTTRx) in people with early stage Huntington’s disease .
George Yohrling, Ph.D., Senior Director of Mission and Science at the HDSA discusses the challenges that come with working with patients with HD, and communicating with their family members and caregivers.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.